Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN3918 open-label single-arm phase 2 study in active paroxysmal nocturnal hemoglobinuria
NL-OMON48163Phase 2Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pozelimab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Adequate control of intravascular hemolysis and Transfusion avoidance. Planned start Apr 2019; status: withdrawn.
02
Drugs
pozelimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON48163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48163.